The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Market Value Trend Is Expected For The Inflammatory Bowel Disease Treatment Market From 2026 To 2030?
The inflammatory bowel disease treatment market has seen significant expansion in recent years. This market is expected to grow from $27.19 billion in 2025 to $29.8 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.6%. Historically, this growth can be attributed to an increased prevalence of ulcerative colitis and Crohn’s disease, greater awareness of available IBD treatment options, the expansion of hospital and retail pharmacy networks, the accessibility of generic aminosalicylates, and the early adoption of biologics in advanced economies.
The inflammatory bowel disease treatment market is anticipated to show significant expansion in the coming years, reaching $43.36 billion in 2030 with a compound annual growth rate (CAGR) of 9.8%. This increase over the forecast period is driven by various factors, such as increased investment in precision medicine, the development of innovative anti-inflammatory therapies, the integration of digital health platforms for monitoring patients, a rise in the adoption of biologics and biosimilars, and the broader availability of IBD treatment in emerging markets. Noteworthy trends during this time include the advancement of personalized IBD therapy, the growing application of biologics in treatment, the development of minimally invasive drug delivery systems, an increased focus on programs for patient adherence, and the expansion of specialty pharmacies for IBD care.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6704&type=smp
What Influential Factors Are Boosting The Inflammatory Bowel Disease Treatment Market Demand?
The growing incidence of Crohn’s disease and ulcerative colitis is a significant driver for the inflammatory bowel disease treatment market. Both Crohn’s disease and ulcerative colitis are types of inflammatory bowel diseases (IBD) that cause inflammation and sores in the digestive tract. The increasing number of cases of these conditions is expected to boost demand for inflammatory bowel disease treatments, as they are widely utilized to reduce bowel inflammation and lessen or prevent medical complications. For instance, in November 2024, according to the Crohn’s & Colitis Foundation, a US-based Non-profit organization, approximately 100,429 children and adolescents in the United States under 20 years old are affected by IBD, encompassing both Crohn’s disease and ulcerative colitis. Among this pediatric population, Crohn’s disease is more common, with a prevalence of 71 per 100,000, compared to 44 per 100,000 for ulcerative colitis. Hence, the rising prevalence of Crohn’s disease and ulcerative colitis is anticipated to drive the inflammatory bowel disease treatment market growth.
What Segment Types Are Included In The Inflammatory Bowel Disease Treatment Market Analysis?
The inflammatory bowel disease treatment market covered in this report is segmented –
1) By Drug Class: Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Other Drug Classes
2) By Type: Crohn’s Disease, Ulcerative Colitis
3) By Route Of Administration: Oral, Injectable
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Aminosalicylates: Mesalamine, Sulfasalazine, Balsalazide
2) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone
3) By TNF Inhibitors: Infliximab, Adalimumab, Certolizumab pegol
4) By IL Inhibitors: Ustekinumab, Guselkumab
5) By Anti-Integrin: Vedolizumab, Natalizumab
6) By JAK Inhibitors: Tofacitinib, Filgotinib
7) By Other Drug Classes: Antibiotics, Immunosuppressants, Other Novel Therapies
Which Trends Are Influencing The Direction Of The Inflammatory Bowel Disease Treatment Market?
Leading firms in the inflammatory bowel disease treatment sector are introducing novel products, including therapies for moderate to severe active ulcerative colitis, aiming to serve broader customer segments, boost sales, and enhance revenue. These treatments for moderate to severe active ulcerative colitis commonly involve pharmaceutical drugs and, on occasion, surgical procedures. As an example, in October 2023, US-based pharmaceutical company Eli Lilly and Company revealed that the U. S. Food and Drug Administration (FDA) had approved Omvoh (mirikizumab-mrkz). This product, available as both an infusion (300 mg/15 mL) and an injection (100 mg/mL), represents the first and only interleukin-23p19 (IL-23p19) antagonist developed for adults suffering from moderately to severely active ulcerative colitis (UC). Omvoh is engineered to target the p19 subunit of IL-23, thereby effectively inhibiting the IL-23 pathway, which plays a significant role in the inflammation leading to UC. The treatment protocol for Omvoh starts with three 300-mg IV infusions, given weekly for four weeks, followed by a maintenance stage consisting of two 100-mg subcutaneous self-injections every four weeks.
Who Are The Firms Contributing To The Inflammatory Bowel Disease Treatment Market Ecosystem?
Major companies operating in the inflammatory bowel disease treatment market are AbbVie Inc., Biogen Inc., Johnson & Johnson, Amgen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Salix Pharmaceuticals Inc., Vifor Pharma AG, Zydus Pharmaceuticals (USA) Inc., Advanced Gastroenterology and Surgery Associates P.A., Atlanta Gastroenterology Associates LLC, Digestive Disease Associates of Rockland P.C., Gastrointestinal Specialists Inc., Illinois Gastroenterology Group LLC, Massachusetts General Hospital, Mayo Clinic, Mount Sinai Health System Inc., The Oregon Clinic – Gastroenterology West P.C.
Access The Complete Inflammatory Bowel Disease Treatment Market Report:
Which Region Commands The Largest Share Of The Inflammatory Bowel Disease Treatment Market?
North America was the largest region in the inflammatory bowel disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflammatory bowel disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Inflammatory Bowel Disease Treatment Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=6704&type=smp
Browse Through More Reports Similar to the Global Inflammatory Bowel Disease Treatment Market 2026, By The Business Research Company
Inflammatory Bowel Disease Treatment Market Report 2026
Crohns Disease Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/crohns-disease-treatment-global-market-report
Rare Inflammatory Disease Treatment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model